Probi AB
STO:PROB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
188.7892
351
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Probi AB
Probi AB
Operating Expenses
Probi AB
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Probi AB
STO:PROB
|
Operating Expenses
-kr207.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-20%
|
|
|
Biogaia AB
STO:BIOG B
|
Operating Expenses
-kr508.9m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Operating Expenses
-kr658.5m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Operating Expenses
-kr5.6B
|
CAGR 3-Years
-131%
|
CAGR 5-Years
-66%
|
CAGR 10-Years
-39%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Operating Expenses
-kr14B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-23%
|
|
|
BioArctic AB
STO:BIOA B
|
Operating Expenses
-kr300.5m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Probi AB
Glance View
Probi AB engages in the development and sale of probiotics. The company is headquartered in Lund, Skane and currently employs 175 full-time employees. The Company’s activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The firm's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The firm is a parent of Probi Food AB and Probi Feed AB.
See Also
What is Probi AB's Operating Expenses?
Operating Expenses
-207.3m
SEK
Based on the financial report for Jun 30, 2024, Probi AB's Operating Expenses amounts to -207.3m SEK.
What is Probi AB's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-20%
Over the last year, the Operating Expenses growth was 2%. The average annual Operating Expenses growth rates for Probi AB have been -5% over the past three years , -2% over the past five years , and -20% over the past ten years .
You don't have any saved screeners yet
